Nasdaq GlobeNewswire

XBiotech Announces Agreement with Cedars-Sinai Medical Center to Evaluate MABp1 in Combination with Onivyde® and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer

Del

AUSTIN, Texas, Sept. 20, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today its agreement with Cedars-Sinai Medical Center located in Los Angeles, California, whereby XBiotech will provide its interleukin-1 alpha antagonist, MABp1, for a Phase I single arm study evaluating the maximum tolerated dose of Onivyde® (Irinotecan liposome injection) and 5-fluorouracil/folinic acid in combination with MABp1 in a cohort of patients with advanced pancreatic adenocarcinoma and cachexia. The study will also assess efficacy using various secondary measures including changes in lean body mass, weight stability, IL-6 levels, overall and progression free survival as well as evaluation of the relationship between treatment tolerance and patient functional status.

Andrew Hendifar, M.D., Medical Oncology lead for the Gastrointestinal Disease Research Group at Cedars-Sinai and Co-Director of Pancreas Oncology, will be leading the study which is planned to enroll a total of 16 patients at the Cedars-Sinai Medical Center. Onivyde will be given intravenously with MABp1 and 5-fluorouracil/folinic acid every two weeks until disease progression.

Dr. Hendifar commented, "The results to date with treatment of MABp1 show much promise as an effective therapy in this setting. I look forward to evaluating this combination therapy to determine its safety and clinical benefit."

Despite decades of clinical trials, the prognosis for advanced pancreatic cancer is poor [1].  The 5-year survival has remained close to 5% and unchanged despite improvements in chemotherapeutics, surgical outcomes, and diagnostic techniques [1, 2].  Advanced pancreatic adenocarcinoma is characterized by progressive weight loss and nutritional deterioration [3].  It is estimated that up to 80% of these patients present with cachexia [4].  This syndrome has been linked not only to survival, but also to alterations in host defenses, functional ability, and quality of life. In a Phase III clinical study, MABp1 was found to improve clusters of symptoms that included reduced pain, fatigue, improved appetite and increased lean body mass. Patients that had these improvements were found to have reduced disease progression and serious adverse events, and about a three-fold improvement in survival.

Other than multi-agent cytotoxic therapy there have been no treatment advances for pancreatic cancer or its associated cachexia. Despite the availability of effective chemotherapy, only between 15-40% of pancreatic cancer patients are able to receive second line treatment. Importantly, cachexia and its associated fatigue and deconditioning, may explain the difficulty in providing continued therapy after progression in the first-line. It is hoped that MABp1 used in combination with Onivyde will help control disease, reduce symptoms and allow patients to receive treatment longer, thereby improving outcomes.

About True Human(TM) Therapeutic Antibodies
XBiotech's True Human(TM) antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech's True Human antibodies have the potential to harness the body's natural immunity to fight disease with increased safety, efficacy and tolerability.

About XBiotech
XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human(TM) proprietary technology. XBiotech currently is advancing a robust pipeline of antibody therapies to redefine the standards of care in oncology, inflammatory conditions and infectious diseases. Headquartered in Austin, Texas, XBiotech also is leading the development of innovative biotech manufacturing technologies designed to more rapidly, cost-effectively and flexibly produce new therapies urgently needed by patients worldwide. For more information, visit www.xbiotech.com.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including declarations regarding management's beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "contemplate," "anticipates," "believes," "estimates," "predicts," "projects," "intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the "Risk Factors" section of certain of our SEC filings. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Contact
Ashley Otero
aotero@xbiotech.com
512-386-2930

1. Li, D., et al., Pancreatic cancer. Lancet, 2004. 363(9414): p. 1049-57.
2. Panagiotarakou, M., et al., Use of supportive care for symptom management in pancreatic cancer: application of clinical research to patient care. Jop, 2012. 13(4): p. 342-4.
3. Splinter, T.A., Cachexia and cancer: a clinician's view. Ann Oncol, 1992. 3 Suppl 3: p. 25-7.
4. Ryan, D.P. and M.L. Grossbard, Pancreatic Cancer: Local Success and Distant Failure. Oncologist, 1998. 3(3): p. 178-188.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: XBiotech, Inc via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Doc re. GE Files Form 8-K13.11.2018 17:30Pressemelding

FAIRFIELD, Conn., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Company General Electric Company ISIN US3696041033 Symbol London: GEC | Paris: GNE Headline Doc re: GE files Form 8-k November 13, 2018 On November 13, 2018, General Electric Company (the "Company") filed a Form 8-K with the U.S. Securities and Exchange Commission ("SEC"), which has been submitted to RNS. It is also available on the SEC's website at http://www.sec.gov and on the Company's website at https://www.ge.com/investor-relations/events-reports. http://www.rns-pdf.londonstockexchange.com/rns/2365H_1-2018-11-13.pdf CONTACT: GE Jennifer Erickson +001 646 682 5620 jennifer.erickson@ge.com This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visi

CloudGenix Named a Finalist in the 2018 CRN® Tech Innovator Awards13.11.2018 17:00Pressemelding

Company’s AppFabric Recognized in the 2018 Enterprise Networking Category SAN JOSE, Calif., Nov. 13, 2018 (GLOBE NEWSWIRE) -- CloudGenix announced today that CRN , ® a brand of The Channel Company, has been recognized as a finalist in the 2018 CRN Tech Innovator Awards. These annual awards honor standout hardware, software, and services that are moving the IT industry forward. In compiling the 2018 Tech Innovator Award list, CRN editors evaluated 300 products across 34 technology categories using several criteria, including technological advancements, uniqueness of features and potential to help solution providers solve end users' IT challenges. CloudGenix’s AppFabric took top honors in the Enterprise Networking category. CloudGenix AppFabric is a revolutionary software-defined wide area networking (SD-WAN) platform that allows businesses to integrate cloud and SaaS applications, create a secure application-defined fabric across any WAN transport, reduce operational cost and complexity

Atico Reports Reserves of 119 Million Pounds of Copper at the El Roble Mine13.11.2018 15:51Pressemelding

VANCOUVER, British Columbia, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Atico Mining Corporation (the “Company” or “Atico”) (TSX.V: ATY | OTC: ATCMF) is pleased to announce the release of an updated NI 43-101 mineral resource and reserve estimate for the El Roble Mine located in Colombia. El Roble is currently in production at a rate of 850tpd and production guidance for the year is 20 million pounds of copper along with 9,850 ounces of gold in 2018. For the first three quarters of 2018, El Roble has produced 16 million pounds of copper and 8,400 ounces of gold or over 80% and 85% of annual forecast production for copper and gold respectively. “Our infill and mine vicinity exploration drilling at El Roble mine has been successful in replenishing mined resources since 2013. The maiden resource study at El Roble mine of 1.5 million tonnes of inferred resource has grown to 1.8 million tonnes of measured and indicated resources, while also having mined over 1 million tonnes of high-grade ore during

New VANTIQ Pronto Drives Modern Event-Driven Systems13.11.2018 15:00Pressemelding

VANTIQ Pronto Dynamic Advanced Event Broker™ enables organizations with real-time business responsiveness across enterprise, cloud and edge events PONTE VEDRA BEACH, Fla., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Today, at the nGage Enterprise Transformation Exchange Summit, VANTIQ announced VANTIQ Pronto, the industry’s first dynamic “Advanced Event Broker” (AEB). IT leaders from across the U.S. learned how Pronto is designed to deliver unique advantages for companies looking to power modern, event-driven applications with the real-time business responsiveness, intelligence and agility required for digital transformation initiatives. VANTIQ Pronto will be generally available to developers on November 30 at no charge for up to 2 million event messages in production per month. According to Gartner, “Application leaders engaged in digital transformation must include event-driven computing in their portfolio of skills and technology, including the key related responsibilities for event brokering

New PubMatic Research Reveals Mobile Header Bidding Volumes Nearly Double as the Technology Extends to In-app Environments13.11.2018 15:00Pressemelding

PubMatic releases Q3 2018 QMI report, highlighting key trends that impact mobile advertising growth REDWOOD CITY, Calif., Nov. 13, 2018 (GLOBE NEWSWIRE) -- PubMatic, the publisher-focused sell-side platform (SSP) for an open digital media future, today released its third Quarterly Mobile Index (QMI) of 2018. The report includes key insights around the growth in mobile app advertising, highlighting trends in mobile video, header bidding and the expansion of cross-channel monetization. The newly released findings will guide publishers and buyers toward smarter programmatic strategy and projected future mobile opportunities. Advertisers are expected to spend more than $180 billion on mobile advertising in 2019 (eMarketer) and so it is imperative to understand where the growth is taking place to plan accordingly. PubMatic’s Q3 2018 QMI Report reveals the top three trends to watch: Mobile Video Reached A Milestone - Advertiser interest is driving global mobile video ad spend growth, creatin

Velox Completes $32M Investment Round, Accelerating Market Penetration and Further Innovating Industrial Direct-to-Shape Digital Printing13.11.2018 14:01Pressemelding

A group of financial and strategic investors back Velox's commercially available, market-proven, disruptive technology ROSH HA'AYIN, Israel, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Today, Velox, the leading developer of the world’s only mass production direct-to-shape (DTS) digital printing technology, completed a $32 million funding round. The round was co-led by JAL Ventures and O.R.T. Technologies Ltd., and joined by strategic investors ALTANA, Evonik as well as existing investors Michael Ilan Management & Investments Ltd. (MILMI), Dr. Shlomo Shamir, and additional private investors. With equipment commercially deployed, and multiple high-value strategic global accounts secured, Velox is seen as an industry standout. Velox’s uniquely formulated inks and proprietary printing process enables it to take digital printing from the domain of special-editions-only into the mass packaging decoration mega market. Investor Quotes: “Our investment in Velox is an expression of our strategic and on-go

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom